Howard A. Burris

71.6k total citations · 19 hit papers
741 papers, 38.2k citations indexed

About

Howard A. Burris is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Howard A. Burris has authored 741 papers receiving a total of 38.2k indexed citations (citations by other indexed papers that have themselves been cited), including 531 papers in Oncology, 298 papers in Pulmonary and Respiratory Medicine and 269 papers in Molecular Biology. Recurrent topics in Howard A. Burris's work include Cancer Treatment and Pharmacology (178 papers), Lung Cancer Treatments and Mutations (130 papers) and Colorectal Cancer Treatments and Studies (114 papers). Howard A. Burris is often cited by papers focused on Cancer Treatment and Pharmacology (178 papers), Lung Cancer Treatments and Mutations (130 papers) and Colorectal Cancer Treatments and Studies (114 papers). Howard A. Burris collaborates with scholars based in United States, United Kingdom and France. Howard A. Burris's co-authors include John D. Hainsworth, Daniel D. Von Hoff, Suzanne F. Jones, F. Anthony Greco, Anna Maria Storniolo, Mace L. Rothenberg, F. Andrew Dorr, Ryan Nelson, Russell K. Portenoy and Manuel Modiano and has published in prestigious journals such as Nature, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Howard A. Burris

727 papers receiving 37.2k citations

Hit Papers

Improvements in survival and clinical benefit with gemcit... 1997 2026 2006 2016 1997 2014 2007 2008 2010 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
    1997 4.6k citations Howard A. Burris, Daniel D. Von Hoff et al. Journal of Clinical Oncology profile →
  2. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    2014 1.9k citations Howard A. Burris et al. profile →
  3. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
    2007 898 citations Howard A. Burris et al. Journal of Clinical Oncology profile →
  4. EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer
    2008 726 citations Howard A. Burris et al. Journal of Clinical Oncology profile →
  5. Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy
    2010 568 citations Howard A. Burris, Ian E. Krop et al. Journal of Clinical Oncology profile →
  6. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    2011 550 citations Johanna C. Bendell, Howard A. Burris et al. Journal of Clinical Oncology profile →
  7. Phase I Safety, Pharmacokinetics, and Clinical Activity Study of Lapatinib (GW572016), a Reversible Dual Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinases, in Heavily Pretreated Patients With Metastatic Carcinomas
    2005 503 citations Howard A. Burris, Suzanne F. Jones et al. Journal of Clinical Oncology profile →
  8. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
    2012 424 citations Jeffrey R. Infante, Lowell L. Hart et al. The Lancet Oncology profile →
  9. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    2014 407 citations Mario Campone, Howard A. Burris et al. Annals of Oncology profile →
  10. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
    2013 383 citations Denise A. Yardley, Howard A. Burris et al. profile →
  11. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
    2019 383 citations Funda Meric‐Bernstam, Charles Swanton et al. The Lancet Oncology profile →
  12. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
    2013 362 citations Howard A. Burris profile →
  13. Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
    2018 357 citations John D. Hainsworth, Funda Meric‐Bernstam et al. Journal of Clinical Oncology profile →
  14. Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
    2018 302 citations Howard A. Burris et al. Journal of Clinical Oncology profile →
  15. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study
    2021 251 citations Milind Javle, Mitesh J. Borad et al. The Lancet Oncology profile →
  16. First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
    2021 192 citations Jeffrey R. Infante, Manish R. Patel et al. profile →
  17. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.
    2022 159 citations Howard A. Burris et al. Journal of Clinical Oncology profile →
  18. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    2022 125 citations Howard A. Burris et al. Journal of Clinical Oncology profile →
  19. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial
    2024 51 citations Howard A. Burris et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Howard A. Burris United States 89 25.4k 13.0k 10.7k 6.2k 4.2k 741 38.2k
Richard Pazdur United States 106 19.8k 0.8× 10.6k 0.8× 10.3k 1.0× 5.2k 0.8× 3.8k 0.9× 596 37.7k
Janet Dancey United States 68 19.9k 0.8× 8.6k 0.7× 15.4k 1.4× 6.2k 1.0× 5.5k 1.3× 205 38.3k
José Baselga United States 98 25.8k 1.0× 19.7k 1.5× 14.1k 1.3× 9.8k 1.6× 3.6k 0.8× 484 46.7k
John D. Hainsworth United States 82 21.5k 0.8× 10.1k 0.8× 12.3k 1.2× 5.2k 0.8× 5.3k 1.2× 631 37.1k
Jean‐Charles Soria France 95 19.7k 0.8× 13.0k 1.0× 12.8k 1.2× 6.8k 1.1× 2.7k 0.6× 679 34.8k
Richard S. Finn United States 76 16.3k 0.6× 9.0k 0.7× 11.6k 1.1× 8.3k 1.3× 3.6k 0.9× 370 38.2k
Fortunato Ciardiello Italy 86 21.9k 0.9× 13.3k 1.0× 11.8k 1.1× 5.5k 0.9× 2.9k 0.7× 643 34.3k
Salvatore Siena Italy 76 26.8k 1.1× 7.6k 0.6× 12.2k 1.1× 7.0k 1.1× 4.7k 1.1× 534 37.8k
Heikki Joensuu Finland 97 12.8k 0.5× 8.4k 0.6× 12.6k 1.2× 6.2k 1.0× 7.1k 1.7× 583 35.5k
Louis Fehrenbacher United States 63 25.3k 1.0× 8.9k 0.7× 10.2k 1.0× 8.0k 1.3× 2.9k 0.7× 157 35.9k

Countries citing papers authored by Howard A. Burris

Since Specialization
Citations

This map shows the geographic impact of Howard A. Burris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Howard A. Burris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Howard A. Burris more than expected).

Fields of papers citing papers by Howard A. Burris

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Howard A. Burris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Howard A. Burris. The network helps show where Howard A. Burris may publish in the future.

Co-authorship network of co-authors of Howard A. Burris

This figure shows the co-authorship network connecting the top 25 collaborators of Howard A. Burris. A scholar is included among the top collaborators of Howard A. Burris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Howard A. Burris. Howard A. Burris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Subbiah, Vivek, Howard A. Burris, & Razelle Kurzrock. (2023). Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer. 130(2). 186–200. 16 indexed citations
2.
Brown, Jacqueline, Michael Method, Erika Hamilton, et al.. (2022). A real-world retrospective study of the use of Ki-67 testing and treatment patterns in patients with HR+, HER2− early breast cancer in the United States. BMC Cancer. 22(1). 502–502. 6 indexed citations
3.
Javle, Milind, Mitesh J. Borad, Nilofer S. Azad, et al.. (2021). Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. The Lancet Oncology. 22(9). 1290–1300. 251 indexed citations breakdown →
4.
Cutsem, Eric Van, Hans Prenen, Kristen Spencer, et al.. (2021). 529 Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors. SHILAP Revista de lepidopterología. A559–A560. 11 indexed citations
5.
6.
Varga, Andréa, Jean‐Charles Soria, Antoine Hollebecque, et al.. (2019). A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(6). 1229–1236. 64 indexed citations
7.
Sonke, Gabe S., Lowell L. Hart, Mario Campone, et al.. (2017). Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Research and Treatment. 167(3). 659–669. 61 indexed citations
8.
Schwartzberg, Lee S., Denise A. Yardley, Anthony Elias, et al.. (2017). A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer. Clinical Cancer Research. 23(15). 4046–4054. 42 indexed citations
9.
Kristeleit, Rebecca, Geoffrey I. Shapiro, Howard A. Burris, et al.. (2017). A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research. 23(15). 4095–4106. 186 indexed citations
10.
André, Fabrice, Sara A. Hurvitz, Angelica Fasolo, et al.. (2016). Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2–Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. Journal of Clinical Oncology. 34(18). 2115–2124. 135 indexed citations
11.
Hoff, Daniel D. Von, Monica Mita, Ramesh K. Ramanathan, et al.. (2016). Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors. Clinical Cancer Research. 22(13). 3157–3163. 215 indexed citations
12.
Tolaney, Sara M., Howard A. Burris, Elaina M. Gartner, et al.. (2014). Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment. 149(1). 151–161. 49 indexed citations
13.
Yardley, Denise A., et al.. (2014). Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial. Breast Cancer Research and Treatment. 148(3). 535–540. 1 indexed citations
14.
Crown, John, Megan Kennedy, Patricia Tresca, et al.. (2013). Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Annals of Oncology. 24(8). 2005–2011. 12 indexed citations
15.
Beeram, Muralidhar, Ian E. Krop, Howard A. Burris, et al.. (2012). A phase 1 study of weekly dosing of trastuzumab emtansine (T‐DM1) in patients with advanced human epidermal growth factor 2–positive breast cancer. Cancer. 118(23). 5733–5740. 74 indexed citations
16.
Burris, Howard A., Jay Tibbitts, Scott N. Holden, Mark X. Sliwkowski, & Gail D. Lewis Phillips. (2011). Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer. Clinical Breast Cancer. 11(5). 275–282. 90 indexed citations
17.
Yardley, Denise A., Howard A. Burris, N. W. Peacock, et al.. (2010). A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Research and Treatment. 123(2). 471–475. 21 indexed citations
18.
Infante, Jeffrey R., Denise A. Yardley, Howard A. Burris, et al.. (2009). Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer. Clinical Breast Cancer. 9(1). 23–28. 15 indexed citations
19.
Burris, Howard A., Charles W. Taylor, Suzanne F. Jones, et al.. (2009). A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies. Clinical Cancer Research. 15(21). 6702–6708. 83 indexed citations
20.
Burris, Howard A., Denise A. Yardley, Suzanne F. Jones, et al.. (2004). Phase II Trial of Trastuzumab Followed by Weekly Paclitaxel/Carboplatin As First-Line Treatment for Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 22(9). 1621–1629. 87 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard Pazdur Breakdown of academic impact, for papers by Janet Dancey Breakdown of academic impact, for papers by José Baselga Breakdown of academic impact, for papers by John D. Hainsworth Breakdown of academic impact, for papers by Jean‐Charles Soria Breakdown of academic impact, for papers by Richard S. Finn Breakdown of academic impact, for papers by Fortunato Ciardiello Breakdown of academic impact, for papers by Salvatore Siena Breakdown of academic impact, for papers by Heikki Joensuu Breakdown of academic impact, for papers by Louis Fehrenbacher
Rankless by CCL
2026